DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR PIPERACILLIN
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Piperacillin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003805 | Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | 1997-11-01 | RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease. |
| NCT00044746 | Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2000-10-01 | Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients. |
| NCT00044759 | Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 1969-12-31 | To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma. |
| NCT00130754 | Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation | Completed | Hadassah Medical Organization | Phase 3 | 2005-02-01 | Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications. Until recently, myeloablative in conjunction with immunosuppressive conditioning was considered mandatory for the elimination of malignant hematopoietic cells and to prevent graft rejection. The aim of allogeneic non-myeloablative stem cell transplantation (NST) is to induce host-to-graft tolerance with fast and durable engraftment of donor stem cells, by means of conditioning, which is well-tolerated by patients. The rationale behind the NST strategy is to induce optimal graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent cells from a matched donor as an alternative to standard high-dose myeloablative chemo radiotherapy. The NST protocol is therefore mainly based on immunosuppression and thus contains fludarabine, low dose busulfan and anti-T-lymphocyte globulin (ATG). Thymoglobuline is a polyclonal rabbit antiserum specific for human T cells used in organ transplantation for induction of tolerance and rejection prevention and treatment. It was also used in stem-cell transplantation (SCT) for the same purposes (e.g. for generation of tolerance and rejection preclusion) as well as a treatment for graft-versus-host disease (GVHD). Data from myeloablative protocols suggest that ATG before SCT significantly reduces the risk for grade III-IV acute GVHD. This does not translate to a reduction in transplant-related mortality (TRM) because of the increased risk for infections and thus survival is unchanged. Extensive chronic GVHD was also significantly shown to be reduced in patients receiving ATG in the myeloablative setting. However, the role of ATG in the NST protocol was never evaluated in a prospective randomized trial. In view of the preliminary data suggesting of an additive effect of ATG in these circumstances we, the investigators at Hadassah Medical Organization, evaluate the effect of ATG in NST by a prospective randomized trial. |
| NCT00167999 | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2005-02-01 | To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units |
| NCT00195286 | Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections. | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2004-06-01 | The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Piperacillin
Condition Name
Clinical Trial Locations for Piperacillin
Trials by Country
Clinical Trial Progress for Piperacillin
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Piperacillin
Sponsor Name
